title: Neoadjuvant anthracycline and trastuzumab for breast cancer: is concurrent treatment safe?
authors.affiliation: Department of Medical Oncology, Institut Jules Bordet, Universite Libre de Bruxelles, 1000 Brussels, Belgium.
authors.forename: Ivana
authors.initials: I
authors.lastname: Bozovic-Spasojevic
authors.forename: Hatem A
authors.initials: HA
authors.lastname: Azim
authors.forename: Marianne
authors.initials: M
authors.lastname: Paesmans
authors.forename: Thomas
authors.initials: T
authors.lastname: Suter
authors.forename: Martine J
authors.initials: MJ
authors.lastname: Piccart
authors.forename: Evandro
authors.initials: E
authors.lastname: de Azambuja
mesh_terms: D018943:Anthracyclines / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab
chemical_list: D018943:Anthracyclines; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human